MONTREAL, April 14 /CNW Telbec/ - ART Advanced Research Technologies Inc.
("ART") (TSX: ARA), a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce its
participation at the annual conference of the American Association for Cancer
Research (AACR) being held at the Anaheim Convention Center in Anaheim,
California, from April 16 to 20, 2005.
ART will showcase the multiwavelength eXplore Optix(TM) system, a
pre-clinical optical molecular imager designed to provide in vivo
biodistribution and pharmacokinetics data, at the GE Healthcare booth
(No. 787) located in the Exhibit Hall C and D of the Anaheim Convention
Center.
About AACR
Founded in 1907, AACR's mission is to accelerate the prevention and cure
of cancer through research, education, communication and advocacy. AACR's
annual meeting attracts more than 12,000 participants who share new and
significant discoveries in the cancer field.
About ART
ART Advanced Research Technologies Inc. is a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries. ART has
developed two products based on its innovative technology. The first is
eXplore Optix(TM), a molecular imaging device designed for monitoring
physiological changes in living systems at the preclinical study phases of new
drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by
industry and academic leaders worldwide to bring new and better treatments to
patients faster. The second is SoftScan(R), a medical imaging device designed
to improve the diagnosis and treatment of breast cancer. ART is
commercializing its products in a global strategic alliance with
GE Healthcare, a world leader in mammography and imaging. ART's shares are
listed on the TSX under the ticker symbol ARA. Visit ART online at www.art.ca
This press release may contain forward-looking statements subject to
risks and uncertainties that would cause actual events to differ materially
from expectations. These risks and uncertainties are described in ART Advanced
Research Technologies Inc.'s regulatory filings with Canadian Securities
Commissions.
